Is Dihexa safe?
Limited EvidenceSide effects, risks, and safety considerations based on available research.
Research status
Dihexa has very limited human safety data. Most information comes from animal studies, in vitro research, or anecdotal reports. This means the true risk profile in humans is largely unknown.
Known concerns & side effects
- ⚠zero published human clinical trials
- ⚠the "millions of times more potent" claim compares potency (effective dose), not efficacy — a lower dose needed does not mean stronger effects
- ⚠HGF/c-Met pathway is implicated in cancer cell growth and metastasis — long-term safety is a significant unknown
- ⚠only available from unregulated research chemical suppliers
- ⚠patent held by Washington State University but never advanced to clinical development
- ⚠extremely limited long-term safety data even in animal models
Use caution with
Relevant safety research
Dihexa improves cognitive function in aged rats via HGF/c-Met signaling
Finding: Dihexa administered intranasally or orally to aged rats improved performance in water maze and novel object recognition tasks, suggesting enhanced memory consolidation and spatial learning.
Limitation: Rat cognitive models have limited translatability to human cognition. No human trials have been conducted. Long-term safety was not assessed.
Frequently asked questions
Is Dihexa safe?
Unknown. There are no human safety studies. The primary concern is that HGF/c-Met signaling promotes cell proliferation and is overactive in many cancers. Whether exogenous HGF enhancement would increase cancer risk in humans is completely untested. This risk alone should give serious pause.
Is Dihexa really millions of times more potent than BDNF?
This claim is misleading. The original research found Dihexa was active at picomolar concentrations (very small amounts), while BDNF requires nanomolar concentrations — about a million-fold difference in dose. But potency (how little you need) is not the same as efficacy (how well it works). A lower effective dose does not mean Dihexa produces stronger cognitive effects than BDNF.
Why hasn't Dihexa gone to human trials?
Despite being patented in 2012, Dihexa has never entered clinical development. The reasons are unclear but may include concerns about the HGF/c-Met pathway's role in cancer promotion, difficulty securing funding, or insufficient preclinical data to justify the safety risk. This is a significant red flag for a compound marketed as a cognitive enhancer.
Full Dihexa Profile
Evidence, timeline, products & more
Take the Peptide Quiz
Get personalized recommendations
Last updated: 2025-03-25
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.